BBR Partners’s Pfizer PFE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $538K | Sell |
19,160
-7,918
| -29% | -$211K | 0.03% | 148 |
|
|
2025
Q4 | $674K | Sell |
27,078
-191
| -0.7% | -$4.82K | 0.04% | 135 |
|
|
2025
Q3 | $695K | Buy |
27,269
+193
| +0.7% | +$4.76K | 0.04% | 130 |
|
|
2025
Q2 | $656K | Sell |
27,076
-5,116
| -16% | -$119K | 0.04% | 124 |
|
|
2025
Q1 | $816K | Sell |
32,192
-9,000
| -22% | -$236K | 0.06% | 109 |
|
|
2024
Q4 | $1.09M | Sell |
41,192
-327
| -0.8% | -$8.87K | 0.08% | 93 |
|
|
2024
Q3 | $1.2M | Sell |
41,519
-505
| -1% | -$14.7K | 0.09% | 79 |
|
|
2024
Q2 | $1.18M | Sell |
42,024
-1,298
| -3% | -$35.7K | 0.1% | 72 |
|
|
2024
Q1 | $1.2M | Buy |
43,322
+296
| +0.7% | +$8.21K | 0.1% | 80 |
|
|
2023
Q4 | $1.24M | Sell |
43,026
-587
| -1% | -$17.7K | 0.13% | 61 |
|
|
2023
Q3 | $1.45M | Buy |
43,613
+886
| +2% | +$31.3K | 0.16% | 53 |
|
|
2023
Q2 | $1.57M | Buy |
42,727
+55
| +0.1% | +$2.14K | 0.17% | 49 |
|
|
2023
Q1 | $1.74M | Buy |
42,672
+803
| +2% | +$34.7K | 0.2% | 45 |
|
|
2022
Q4 | $2.15M | Buy |
41,869
+343
| +0.8% | +$16.4K | 0.24% | 39 |
|
|
2022
Q3 | $1.82M | Sell |
41,526
-9,741
| -19% | -$473K | 0.23% | 48 |
|
|
2022
Q2 | $2.69M | Buy |
51,267
+1,500
| +3% | +$76.4K | 0.31% | 39 |
|
|
2022
Q1 | $2.58M | Buy |
49,767
+16,516
| +50% | +$857K | 0.24% | 52 |
|
|
2021
Q4 | $1.96M | Buy |
33,251
+306
| +0.9% | +$15.2K | 0.23% | 55 |
|
|
2021
Q3 | $1.42M | Sell |
32,945
-1,277
| -4% | -$56.6K | 0.12% | 69 |
|
|
2021
Q2 | $1.34M | Sell |
34,222
-7,913
| -19% | -$308K | 0.11% | 72 |
|
|
2021
Q1 | $1.53M | Buy |
42,135
+2,898
| +7% | +$103K | 0.13% | 63 |
|
|
2020
Q4 | $1.44M | Sell |
39,237
-1,904
| -5% | -$69.8K | 0.12% | 64 |
|
|
2020
Q3 | $1.43M | Buy |
41,141
+9,002
| +28% | +$316K | 0.12% | 64 |
|
|
2020
Q2 | $997K | Sell |
32,139
-16,694
| -34% | -$567K | 0.13% | 76 |
|
|
2020
Q1 | $1.51M | Sell |
48,833
-15,676
| -24% | -$534K | 0.23% | 52 |
|
|
2019
Q4 | $2.4M | Buy |
64,509
+15,675
| +32% | +$558K | 0.26% | 47 |
|
|
2019
Q3 | $1.67M | Buy |
48,834
+113
| +0.2% | +$4.11K | 0.25% | 37 |
|
|
2019
Q2 | $2M | Sell |
48,721
-1,485
| -3% | -$59K | 0.32% | 34 |
|
|
2019
Q1 | $2.02M | Buy |
50,206
+7,547
| +18% | +$302K | 0.26% | 53 |
|
|
2018
Q4 | $1.77M | Buy |
42,659
+4,610
| +12% | +$191K | 0.23% | 53 |
|
|
2018
Q3 | $1.59M | Hold |
38,049
| – | – | 0.23% | 39 |
|
|
2018
Q2 | $1.31M | Buy |
38,049
+12,500
| +49% | +$427K | 0.22% | 40 |
|
|
2018
Q1 | $860K | Buy |
+25,549
| New | +$878K | 0.15% | 35 |
|
Other funds holding PFE
VCM
VPM
BBR Partners's PFE Position: Q1 2026 in Review
BBR Partners reduced its Pfizer (PFE) stake by 29% in Q1 2026, selling an estimated $211K and leaving 19,160 shares worth $538K. The position accounts for 0.03% of the portfolio, ranked #148.
BBR Partners first reported a position in PFE in Q1 2018 and has held it in 33 quarters since. The position peaked at $2.69M in Q2 2022. 2,936 funds tracked by Wall St. Rank hold PFE as of Q1 2026.
- BBR Partners held 19,160 shares of Pfizer worth $538K as of Q1 2026.
- BBR Partners sold 7,918 Pfizer shares in Q1 2026, an estimated $211K.
- Pfizer made up 0.03% of BBR Partners's portfolio in Q1 2026, its #148 holding.
- BBR Partners first reported a position in Pfizer in Q1 2018 and has held it in 33 quarters since.
- BBR Partners's Pfizer position peaked at $2.69M in Q2 2022.
- 2,936 funds tracked by Wall St. Rank held Pfizer as of Q1 2026.
Based on BBR Partners's 13F filing for Q1 2026, filed 12 May 2026.